AI주식인사이트AI Stock Insight
C

차바이오텍

085660KOSDAQ

51.9 / 100

Reference Date: 2026-09-08

Financial Score15.5 / 40
News Sentiment19.4 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Cha BioTech primarily operates in umbilical cord blood storage, stem cell research, cell therapy development, anti-aging services, and consulting. The company also engages in pharmaceuticals, global CDMO, and international healthcare network expansion through its major subsidiaries. In 2024, revenue was distributed as 61.06% in medical services, 10.43% in product sales, and 28.51% in other services.

Number of Employees

354people

Average Salary

51.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.93Industry Average 1.204.0Point

In line with industry avg

ROE
-19.32Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
51.30Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲15.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼252.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -7.4% (declining, 3yr)

Detailed News Sentiment

12 totalPositive 9Neutral 0Negative 3Average Sentiment Score 77.5

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 8,090Won52-week high 23,85052-week low 7,920
1-month return1.0Point

1m -13.01% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-09-03
  • Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-08-18
  • Neutral타법인주식및출자증권취득결정2026-08-18
  • Neutral반기보고서 (2026.06)2026-08-13